These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 10442353)

  • 21. Biochemical and clinical pharmacology of 5-fluorouracil.
    Schilsky RL
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):13-8. PubMed ID: 9830619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
    Keith B; Guo XD; Zentko S; Harold N; Schuler B; Quinn M; Shapiro J; Grem JL
    Clin Cancer Res; 2002 May; 8(5):1045-50. PubMed ID: 12006517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New drugs in therapy of colorectal cancer: preclinical studies.
    Rustum YM; Cao S
    Semin Oncol; 1999 Dec; 26(6):612-20. PubMed ID: 10606254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo effect of 5-ethynyluracil on 5-fluorouracil metabolism determined by 19F nuclear magnetic resonance spectroscopy.
    Adams ER; Leffert JJ; Craig DJ; Spector T; Pizzorno G
    Cancer Res; 1999 Jan; 59(1):122-7. PubMed ID: 9892196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics.
    Mattison LK; Soong R; Diasio RB
    Pharmacogenomics; 2002 Jul; 3(4):485-92. PubMed ID: 12164772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy.
    Mercier C; Ciccolini J
    Clin Colorectal Cancer; 2006 Nov; 6(4):288-96. PubMed ID: 17241513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies.
    Ochoa L; Hurwitz HI; Wilding G; Cohen D; Thomas JP; Schwartz G; Monroe P; Petros WP; Ertel VP; Hsieh A; Hoffman C; Drengler R; Magnum S; Rowinsky EK
    Ann Oncol; 2000 Oct; 11(10):1313-22. PubMed ID: 11106122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil.
    Yamada Y; Hamaguchi T; Goto M; Muro K; Matsumura Y; Shimada Y; Shirao K; Nagayama S
    Br J Cancer; 2003 Sep; 89(5):816-20. PubMed ID: 12942110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. UFT plus oral leucovorin calcium (Orzel) and radiation in combined modality therapy: a comprehensive review.
    Minsky BD
    Int J Cancer; 2001 Feb; 96(1):1-10. PubMed ID: 11241325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase.
    Haaz MC; Fischel JL; Formento P; Renée N; Etienne MC; Milano G
    Cancer Chemother Pharmacol; 1996; 38(1):52-8. PubMed ID: 8603452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
    Okuda H; Ogura K; Kato A; Takubo H; Watabe T
    J Pharmacol Exp Ther; 1998 Nov; 287(2):791-9. PubMed ID: 9808711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.
    Baker SD; Khor SP; Adjei AA; Doucette M; Spector T; Donehower RC; Grochow LB; Sartorius SE; Noe DA; Hohneker JA; Rowinsky EK
    J Clin Oncol; 1996 Dec; 14(12):3085-96. PubMed ID: 8955653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer.
    Schmoll HJ
    Anticancer Drugs; 2003 Oct; 14(9):695-702. PubMed ID: 14551502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer.
    Nakagawa T; Tanaka F; Takata T; Matsuoka K; Miyahara R; Otake Y; Yanagihara K; Fukushimab M; Wada H
    J Surg Oncol; 2002 Oct; 81(2):87-92. PubMed ID: 12355409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil (review).
    Milano G; Etienne MC
    Anticancer Res; 1994; 14(6A):2295-7. PubMed ID: 7825962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical development of eniluracil: enhancing the therapeutic index and dosing convenience of 5-fluorouracil.
    Paff MT; Baccanari DP; Davis ST; Cao S; Tansik RL; Rustum YM; Spector T
    Invest New Drugs; 2000 Nov; 18(4):365-71. PubMed ID: 11081572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
    Ogura K
    Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Tumoral dihydropyrimidine dehydrogenase expression and efficacy of 5-fluorouracil plus leucovorin plus UFT therapy in patients with colorectal cancer].
    Ishida H; Ohsawa T; Nakada H; Yokoyama M; Inokuma S; Shirakawa K; Yamada H; Hashimoto D
    Gan To Kagaku Ryoho; 2004 Jun; 31(6):883-7. PubMed ID: 15222105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclophosphamide augments the anti-tumor efficacy of uracil and tegafur by inhibiting dihydropyrimidine dehydrogenase.
    Nio Y; Iguchi C; Kodama H; Itakura M; Hashimoto K; Koike M; Toga T; Maruyama R; Fukushima M
    Oncol Rep; 2007 Jan; 17(1):153-9. PubMed ID: 17143493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluorouracil and the new oral fluorinated pyrimidines.
    Kuhn JG
    Ann Pharmacother; 2001 Feb; 35(2):217-27. PubMed ID: 11215843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.